Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists
Abstract
The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Drug Administration (US FDA)- and European Medicines Agency (EMA)-approved indications and may be used to increase platelet counts in a variety of conditions. Current indications for available TPO-RAs include treatment of chronic immune thrombocytopenia (ITP) in cases of insufficient response to prior treatment...
Paper Details
Title
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists
Published Date
Jun 23, 2021
Journal
Volume
81
Issue
11
Pages
1285 - 1305
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History